BioNTech reports strong first half, expects demand to grow

BERLIN (AP) — BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, has reported higher revenue and net profit in the first half of the year. The German pharmaceutical company said Monday that it expects demand to grow as it releases updated vaccines to target new omicron strains. BioNTech said the dynamic nature of the pandemic has led to changes in orders and revenue but that it expects a strong end to the year. It said it plans to release revamped vaccines tailored to the latest omicron variants as early as October 2022, which could lead to a fall booster campaign.